Search
BeiGene Reports Positive Outcomes from Soticlestat Clinical Trial
2025-08-30 /
Read about 0 minute
Author：小编
BeiGene has announced encouraging results from its Phase 1/2 clinical study of soticlestat, an investigational BCL2 inhibitor designed to treat mantle cell lymphoma. The company intends to showcase the comprehensive data at an upcoming academic conference and submit regulatory applications to the authorities in the United States, Europe, and various other regions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
